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Introduction
The development of tumors and tumor blood vessels is reciprocally dependent, 1,2 so that anticancer strategies targeting both compartments should be advantageous. Cancer gene therapy clinical trials currently rely mostly on destructive strategies including: (1) the delivery of costimulatory molecules/cytokines to enhance cellmediated killing of the malignant cells; (2) the transfer of a conditional cytotoxic gene directly within the tumor; and (3) the introduction of a tumor suppressor gene to drive the malignant cells into apoptosis. 3 The delivery of a secreted inhibitor of tumor angiogenesis with an adenovirus would thus represent a conceptually different, possibly synergistic, approach to fight cancer. Peptidic angiogenesis inhibitors such as angiostatin, 4 uPA/uPAR antagonists, 5, 6 platelet factor-4, 7 or thrombospondin 8 have been described. Among them, the amino-terminal fragment of urokinase (ATF) is of particular interest because it can also exert a direct effect on the tumor cells and inhibit metastasis in experimental models. elements in tumor biology because they control cell motility, tissue remodeling and the bioavailability of angiogenic factors. For example, uPA/uPAR complex formation at the cell surface is required for efficient activation of plasmin, a wide range protease that can degrade components of the basement membrane and the extracellular matrix (eg vitronectin, laminin, fibronectin), a prerequisite for tumor cell invasion. 12, 13 Plasmin also amplifies proteolysis by converting inactive zymogens into active metalloproteinases. 14, 15 The precise distribution of uPAR apparently concentrates uPA at the leading edge of migrating cells, 16 generating a fully activated proteolytic cascade in front of the invadopode. uPAR also exhibits a vitronectin binding site which is distinct from that for uPA, 17 and it binds to and modulates the function of cellular integrins. 18, 19 The strength of the interaction of uPAR with vitronectin can be changed by concurrent uPAR occupancy by uPA, plasmin-dependent hydrolysis of vitronectin and uPA/PAI-I-dependent internalization of uPAR. 20 In such a scheme, uPAR-dependent cellular migration would proceed upon transient attachment to and then detachment from vitronectin. Finally, uPA and plasmin activate morphogenic or angiogenic factors such as VEGF, HGF, FGFs and TGF␤, further supporting cell-associated uPA in controlling cell migration and angiogenesis. [21] [22] [23] [24] [25] The relevance of targeting uPA and uPAR for cancer therapy is supported by epidemiological studies in which high level expression of uPA and uPAR are correlated with a poor prognosis in a number of malignancies, including ovarian, breast, gastric, brain and lung cancer. [26] [27] [28] [29] [30] [31] Clinical observations also indicate the presence of enhanced uPA activity at the invasive edge of the tumors. 32 Melanoma induced by DMBA and croton oil also do not progress to a malignant stage in uPAdeficient mice, 33 further outlining the critical importance of uPA for tumor establishment and progression. uPA binds to uPAR by its light chain fragment, also known as amino-terminal fragment (ATF, residues 1-135). This interaction involves the EGF-like domain of ATF (residues 1-46) and it exhibits species restriction: this is the case between mice and humans for which critical residues 19-32 are not conserved. [34] [35] [36] Preclinical data indicate that ATF-based antagonists constitute potent anticancer molecules. For example, intraperitoneal bolus injections of a human ATF-based antagonist has been shown to inhibit lung metastases of human tumor cells grown in athymic mice, with no significant effect on primary tumor growth. 9 In another study, intraperitoneal injections of peptides from murine ATF inhibited both primary tumor growth and dissemination. 10 Disruption of cell surface uPA/uPAR also inhibited bFGF-or VEGFinduced angiogenesis in an artificial bFGF-enriched extracellular matrix model. 6 In this study, we have used xenograft and syngeneic murine models to assess the antitumoral effects that follow local or systemic administration of a defective adenovirus expressing a secretable uPAR antagonist of murine origin (AdmATF).
Results

Molecular and functional characterization of AdmATF
AdmATF is an E1E3-deleted adenovirus that expresses murine ATF from the CMV promoter, whereas AdCO1 is an 'empty' otherwise isogenic control adenovirus ( Figure 1a ). As shown in Figure 1b , a 0.5 kb ATF-specific poly(A)+ RNA was synthesized following infection of MDA-MB-231 with AdmATF. A uPA-immunoreactive peptide with a molecular weight of mature ATF (15 kDa) was also specifically present in the culture medium from 293 cells infected with AdmATF (Figure 1c ), or following AdmATF infection of LLC or MDA-MB-231 cells (data not shown).
LLC cell-associated plasminogen activation was measured to assess the functionality of the secreted antagonist. As illustrated in Figure 2a , a paracrine inhibition of plasmin activity was specifically observed upon addition of the culture medium from AdmATF-infected 293 cells. An in vitro cell invasion assay confirmed the functionality of AdmATF: upon infection of LLCs cells in conditions that transduced 65% of the cells (ie a multiplicity of infection of 300 plaque-forming units per cell), the number of cells that had migrated through a Matrigel-coated membrane was reproducibly reduced by 68% and 75% after 12 h and 24 h p.i., respectively as compared with AdCO1-infected control cells (Figure 2b ).
AdmATF inhibits tumor growth and establishment by targeting angiogenesis
Adenovirus-mediated delivery of the uPA/uPAR antagonist was studied in a pre-established human breast xenograft model (MDA-MB-231) implanted into athymic mice. Murine ATF should have only marginal effects on the tumor cells in this model as the affinity of murine uPA for human uPAR is several orders of magnitude lower than that for murine uPAR, allowing the antitumoral effects that result from the sole inhibition of angiogenesis to be assessed specifically. Eleven days after subcutaneous tumor cell inoculation, a single intratumoral virus injection was performed, and tumor growth was monitored. After 9 days, a sustained and significant (P Ͻ 0.05) arrest of tumor growth started to establish within the AdmATF-injected group (Figure 3a) , and correlated with the presence of ATF-immunoreactive material within the tumor (data not shown). In another experiment, blockage of tumor growth was evident up to 52 days after infection at which time intratumoral angiogenesis was assessed by von Willebrand factor-immunostaining. 37 Neovascular hot spots were first identified at low magnification and positive microvessels were counted at ×200 magnification (Figure 4a and b) . The results indicated a very significant reduction of the vascularization of AdmATF-injected tumors for which an average of 4.0 ± 2.9 vessels per field (n = 5) were detected relative to 36 ± 6 (n = 5) for AdCO1-injected tumors (P Ͻ 0.01). In this assay, PBS-injected control tumors exhibited a higher number of vessels (56 ± 4; n = 5), perhaps reflecting the use of the ␣ V ␤ 3 integrin for adenovirus infection, 38 a cell surface receptor somehow involved in angiogenesis. 39 Another remark-b a
Figure 2 Functional characterization of AdmATF. (a) The culture medium of AdmATF-infected cells inhibits plasminogen conversion into plasmin at the surface of LLC cells (see Materials and methods). 293 Refers to the supernatant of mock-infected cells. (b) Infection of LLC cells for 24 h with AdmATF (right panel) specifically inhibits cell invasiveness relative to AdCO1-infected cells (left panel). Testing was done in triplicate
and similar results were obtained in a separate experiment.
able feature that emerged was the efficacy with which AdmATF prevented neovascularization at the vicinity of the tumor mass, whereas AdCO1-injected control tumors remained capable of 'attracting' adjacent vessels ( Figure  4c and d).
To assess the effect of AdmATF infection on tumor establishment and progression, MDA-MB-231 cells were infected for 24 h at a multiplicity of infection of 50 plaque forming units per cell, resuspended in 120 l PBS and 80 l ice-cold Matrigel before subcutaneous implantation (1.3 × 10 6 cells) into the dorsa of nude mice. Tumors became apparent in the AdCO1-treated group as early as 7 days after implantation. At day 25, a tumor of limited size was apparent in only one animal from the AdmATFtreated group (n = 5), in sharp contrast to the large tumors present in four out of five animals from the AdCO1-infected group. Again, the smaller tumor from the AdmATF-injected group was less vascularized than those from the AdCO1-injected group (data not shown).
AdmATF inhibits tumor cells dissemination and metastasis
The effects of AdmATF on tumor cell dissemination were then assessed in the Lewis lung carcinoma (LLC) syngeneic model, a vascularized and aggressive model in which death occurs following massive tumor cell dis- semination to the lungs as early as 16 days after s.c. tumor cell inoculation. Five days after grafting, the tumors were injected with PBS, or 10 9 p.f.u. of AdmATF or AdCO1, and tumor growth was monitored until day 15 after infection. A significant inhibition (P Ͻ 0.05) was again specifically observed in the AdmATF-treated group (Figure 3b ). This inhibitory effect was particularly evident late after infection, very likely because of lesser requirements of smaller tumors for angiogenesis-dependent tumor growth. 1 In a separate experiment, tumorbearing animals were virally infected and the tumors extracted at day 5 and day 15 after infection for macroscopic inspection. Whereas AdCO1-injected control tumors displayed an intense vascularization at both timepoints, AdmATF-injected tumors again displayed only marginal vascularization ( Figure 5 ). In this model, the Tumor cell dissemination to the lungs was assessed on paraffin sections stained with hematoxylin and eosin: whereas metastatic nodules were apparent 16 days after infection for all animals injected with PBS (n = 8), and for seven out of nine animals injected with the control virus, only three out of the 10 animals from the AdmATFtreated group scored positive in this assay. As illustrated in Figure 6 , the mean number of metastatic foci per lung section was also significantly reduced (P Ͻ 0.05) in this group: 2.7 ± 1.7 relative to 6.3 ± 3.9 and 6.6 ± 3.1 for the AdCO1-treated and PBS-treated groups, respectively. That tumor cell dissemination was not completely abolished following AdmATF treatment most likely reflects the agressiveness of the LLC model, as tumor cells may have already started to spread out at the time of AdmATF infection. Furthermore, LLC cells are not highly susceptible to adenovirus infection and a single intratumoral injection may not have reached the optimal dose for efficacy.
A liver metastatic model 40 was then used to ask whether a systemic administration of AdmATF could suppress subsequent tumor challenge. AdmATF and control virus (5 × 10 9 p.f.u.) were administered in the sinus of 6-8-week-old nude mice on day 1 (n = 7), before intrasplenic injection of human colon carcinoma LS174T cells on the following day. Macroscopic (Figure 7 ) and histological (data not shown) examinations of the liver 30 days after infection demonstrated a marked reduction (P Ͻ 0.05) of the number of metastases in the AdmATF-b a
Figure 5 AdmATF inhibits LLC tumor vascularization. (a) Representative tumors from AdCO1-treated (left) and AdmATF-treated groups are shown 5 days after infection. (b) A representative tumor from the AdCO1-treated (upper panel) or the AdmATF-treated group (lower panel) is shown 15 days after infection. All photographs were taken at the same magnification.
injected group (2.9 ± 3.0) relative to the AdCO1 control group (11.4 ± 5.5). These numbers translated into a significant (P Ͻ 0.05) increase of the liver weight within the AdCO1-injected group (1.8 ± 0.3 versus 1.2 ± 0.2).
Discussion
We have assessed in mice the antitumoral effects that specifically follow the administration of AdmATF, a defective recombinant adenovirus that expresses a secretable antagonist of urokinase (uPA) binding to its cell surb a
Figure 6 Intratumoral injection of AdmATF inhibits LLC tumor cell dissemination. A lung section from a representative animal from the AdCO1-treated group (a) and the AdmATF-treated group (b) is shown at day 16 after infection. Tumor nodules are indicated (arrows).
face receptor (uPAR). Three murine tumor models were used in this study: (1) a human xenograft model (MDA-MB-231) implanted into a nude mice model to evaluate the action of murine ATF on (murine) angiogenesis with little, if any, direct action on the tumor; (2) a syngenic C57BL/6 model (Lewis lung carcinoma) to study the effect of AdmATF on tumor cell dissemination to the lungs; and (3) a liver metastatic model in nude mice. The overall results emphasize the potential of antagonizing cell-associated urokinase with a recombinant adenovirus to inhibit tumor angiogenesis and metastasis for cancer gene therapy. First, AdmATF was shown to inhibit primary tumor growth in pre-established syngeneic and xenograft murine models and this effect correlated with a marked inhibition of angiogenesis within and at the vicinity of the tumor mass (Figures 4 and 5) . Due to the strong specificity of uPA/uPAR complex formation between mouse and man, the inhibition of tumor growth in the MDA-MB 231 xenograft model most likely resulted mainly from an inhibition of angiogenesis, further supporting the importance of targeting the tumor vasculature to fight cancer. 41 inhibition of cell-associated proteolysis (Figure 2a ) and invasiveness (Figure 2b ). Alternatively, AdmATF may have also inhibited tumor cell dissemination by restricting tumor cell access to the vasculature ( Figure 5 ). Indeed, growing capillaries exhibit a fragmented basal membrane 44 that connects the tumor mass to the vasculature. 45 Finally, we have shown that AdmATF delivered systematically could protect against subsequent tumor challenge in the LS174T model. Depending on the model, adenovirus-mediated secretion of mATF apparently functioned by inhibiting tumor and/or endothelial cell invasion by targeting uPAdependent pericellular proteolysis and uPAR-dependent cell motility: (1) the disruption of cell surface uPA/uPAR is known to block the activation of plasminogen and urokinase, preventing subsequent activation of the proteolytic cascade required for invasion; [12] [13] [14] [15] [16] and (2) uPA/uPAR can also act as transient, reversible and cyclic adhesion sites promoting cell locomotion on vitronectin matrices. 20 Accordingly, the occupancy of uPAR by ATF may have blocked migration by converting these transient adhesion sites into stable cell/matrix contacts. The inhibition of angiogenesis that occurred in AdmATFtreated mice might also have resulted from a concurrent action of ATF in hampering the bioavailability of angiogenic factors. [21] [22] [23] [24] [25] Because the dialogue between cancer and endothelial cells is of a 'symbiotic' nature, 2 ATF therapy may be particularly relevant because of its potential to target both the tumoral and endothelial compartments.
Malignant tumors are life-threatening because they invade and abrogate the function of vital organs at distant sites, emphasizing the importance of targeting tumor angiogenesis and dissemination to fight cancer. The growth of solid tumors is indeed angiogenesis-dependent, 42 and metastases have a higher apoptotic index in the absence of neovascularization. 46 Suppression of angiogenesis with recombinant viruses therefore may constitute a clinically relevant approach for cancer gene therapy as recently illustrated with platelet factor-4 and angiostatin. 47, 48 It is also considered that such a strategy will benefit from the availability of viral vectors allowing long-term transgene expression to increase efficacy. 49, 50 Finally, since activated endothelial cells 5, 51 and most solid tumors express uPAR, virus-mediated ATF delivery, alone or in combination therapies with cytotoxic strategies (for example, see Ref. 30 ), may be particularly potent because this broad cell invasion inhibitor is more than an inhibitor of angiogenesis sensus stricto.
Materials and methods
Recombinant adenoviruses
The murine uPA gene (including its signal peptide) was isolated from plasmid pDB1519, 34 restricted by XbaI and NsiI, and residues 128 to 135 followed by a stop codon were reintroduced as a synthetic fragment. The ATF gene was then inserted between the CMV immediate-early promoter (extending from position −603 to −15) and the SV40 late polyadenylation signal sequence. The resulting plasmid (pEM8-mATF) carries the first 6.3 kb of the Ad5 genome except that the ATF expression cassette is inserted in place of the E1 genes (Figure 1a) . AdmATF was constructed in 293 cells by homologous recombination between pEM8-mATF and ClaI-restricted AdRSV␤Gal DNA. 52 Individual plaques were isolated on to 293-derived cell monolayers, amplified onto fresh 293 cells and viral stocks were prepared (for a review see Ref. 53) . AdCO1 is a control virus that is identical to AdmATF except that it does not carry the ATF expression cassette. Unless otherwise stated, MDA-MB-231 cells and Lewis lung carcinoma (LLC) cells were infected at a multiplicity of infection of 300 p.f.u per cell, translating into 80 and 65% of virally transduced cells, respectively.
Northern blot analysis Subconfluent MDA-MB-231 cells were virally infected for 24 h, and total RNA was extracted (RNAzol, Biogentex, Seabrook, TX, USA). Polyadenylated RNAs were run in a 1% formaldehyde agarose gel, and transferred onto Hybond N membranes (Amersham, Buckinghamshire, UK). The membranes were prehybridized with denatured sonicated salmon sperm DNA (100 g/ml) for 1 h at 42°C in 10 ml of 50% deionized formamide, 0.2% SDS, 5 × Denhardt's solution, and incubated overnight with a random-primed ( 32 P)-labeled 1 kb XbaI-HindIII fragment from the murine uPA cDNA. 34 Membranes were washed twice in 2 × SSC/0.1% SDS for 1 h at 50°C, once in 0.1 × SSC for 30 min and exposed to Kodak (Rochester, NY, USA) XAR-5 films for 1 h at RT.
Western blot analysis
Supernatants from virally infected cells were collected 48 h after infection, run in a 12.5% SDS-polyacrylamide gel (400 g of protein per lane), before transfer on to a nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). After 1-h incubation in blocking buffer, the membranes were incubated for 1 h with a polyclonal serum raised against murine uPA (Pr R Lijnen, Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium), then for 1 h with a horseradish peroxidase-conjugated goat anti-rabbit serum (Dako, Glostrup, Denmark). Membranes were washed three times in PBS-Tween buffer, and 3-amino-9-ethyl-carbazole was added for 5 min. Immunodetection of mATF within the tumor extracts was assessed as follows. Briefly, the tumors were removed at different days after infection, frozen in liquid nitrogen, powdered and 0.5 ml of lysis buffer (10 mm NEM, 1% Triton X100, 1 mm PMSF, 0.1 m NH 4 OH) was added before a 1-h incubation on ice. Tumor extracts were collected by centrifugation at 10 000 g at 4°C and 500 g of protein were used for Western blot analysis.
Inhibition of cell-associated proteolysis
Endogenous uPA was first removed from the surface of LLC cells by a 3-min acidification in glycine-HCl (pH 3), followed by incubation in 0.5 m HEPES buffer (pH 7). The cells were then incubated at 37°C for 20 min with the supernatant of AdCO1-or AdmATF-infected 293 cells. After three washes in PBS/0.1% BSA, they were incubated at 37°C for 20 min with 1 nm of murine uPA (Pr R Lijnen, Leuven, Belgium). Unbound uPA was removed by washing in PBS, and cell-associated uPA was quantified by adding 0.4 m of human plasminogen and plasmin substrate S-2251 (Kabi Vitrum, Stockholm, Sweden).
In vitro invasion assay LLC cells were detached with 1 mm EDTA 24 h after infection, washed in PBS, and resuspended in FCS-free DMEM medium supplemented with 0.1% BSA. Invasion assays were carried out in a 12-well Transwell unit (Costar, Cambridge, MA, USA) as described. 11 Briefly, polycarbonate filters of 12 m pore size were coated with 160 g Matrigel (Becton Dickinson France, le Pont-deChaix, France) and dried. The lower chambers of the Transwell units were filled with human fibroblast-conditioned medium containing 10 ng/ml EGF, and the upper chambers were seeded with 3 × 10 5 infected cells. After 12-and 24-h incubation at 37°C, the number of cells that had reached the lower chamber was counted following staining with Meyer's hematoxylin. The experiments were performed in triplicate.
Tumor models Cultured MDA-MB-231 cells (human breast carcinoma, ATCC HTB 26) were harvested, washed, resuspended in PBS at 1.5 × 10 7 cells/ml, and 3 × 10 6 cells were injected subcutaneously into the dorsa of 6-7-week-old nude mice. When the tumors had reached a volume of 15-20 mm 3 (ie after 11 days), an intratumoral injection of 10 9 p.f.u. of AdmATF (n = 10), AdCO1 (n = 10), or PBS (n = 10) was carried out, and tumor growth was monitored. The extent of intratumoral vascularization was assessed by von Willebrand factor-immunostaining of tumor sections as described. 37 Briefly, tumor tissues were fixed overnight in acetic acid 5%, absolute ethyl alcohol 75%, formalin 2%, water, 18%, transferred to 100% ethanol, embedded in paraffin and 5-m sections were prepared. After toluene treatment and rehydration, they were permeabilized with 2 g/ml proteinase K at 37°C for 15 min and endogenous peroxidase activity was quenched by 0.3% H 2 O 2 for 15 min. The sections were then washed in PBS, incubated for 15 min with 7.5% BSA, after which a rabbit polyclonal serum raised against human von Willebrand factor (Dako; dilution 1/200) was added for 30 min. After three washes in PBS, the sections were incubated with biotinylated goat anti-rabbit IgG antibodies for 30 min, washed and incubated with streptavidin-peroxidase for 15 min before addition of 3-amino-9-ethylcarbazole. Meyer's hematoxylin was used for counterstaining.
LS174T human colon carcinoma cells (ATCC CCL 188) were cultured in RPMI 1640 with 15% FCS. The cells were harvested using trypsin-EDTA, washed twice and resuspended in serum-free RPMI supplemented with 1 U/ml of sodium-heparinate solution. Nude mice, 7-8 weeks old were given a single irradiation dose (5 Gy) 2 days before tumor grafting as described. 40 The next day, 5 × 10 9 p.f.u. of AdmATF or AdCO1 were injected intravenously. On the following day, 3 × 10 6 cells were surgically injected into the spleen and the number of liver metastases was counted 30 days after tumor grafting.
Lewis lung carcinomas (LLCs) were serially passaged on to C57BL/6 syngeneic mice. Briefly, C57BL/6 implanted subcutaneously with a LLC tumor were killed when the tumor had reached a volume of 600-1200 mm 3 . Tumor cells were resuspended in a 0.9% saline solution following filtration through a cotton sieve, and 2 × 10 6 cells (0.5 ml) were subcutaneously implanted to the dorsa of 6-7-week-old C57BL/6 female mice. After 5 days, the tumors (approximately 20 mm 3 ) were injected with PBS (n = 8), or 10 9 p.f.u. (0.2 ml) of AdCO1 (n = 10) or AdmATF (n = 10). Primary tumor growth was monitored until day 16 after infection and the data analyzed with the Student's t test. Lung tissues were removed at this time, fixed overnight in acetic acid 5%, absolute ethyl alcohol 75%, formalin 2%, water 18%, and embedded in 5 m paraffin sections. After hematoxylin and eosin staining, the mean number of metastatic nodules was assessed on three independent sections at a magnification of ×200.
Statistical analysis
Unless otherwise indicated, results are expressed as a mean value ± its standard deviation (s.d.), and the MannWhitney U test was used for statistical analysis.
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